HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Eric J. Devaney Edward L. Bove Jennifer C. Hirsch Richard G. Ohye Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Konuma, T. Articles by Ohye, R. G. Search for Related Content PubMed PubMed Citation Articles by Konuma, T. Articles by Ohye, R. G. Related Collections Congenital - cyanotic

---

Original Articles: Pediatric Cardiac

Performance of CryoValve SG Decellularized Pulmonary Allografts Compared With Standard Cryopreserved Allografts

Divisions of Pediatric Cardiovascular Surgery and Pediatric Cardiology, University of Michigan Medical School, Ann Arbor, Michigan

Accepted for publication June 1, 2009.

^_* Address correspondence to Dr Ohye, 5144 CVC/SPC 5864, 1500 East Medical Center Dr, Ann Arbor, MI 48109 (Email: ohye{at}umich.edu).

Presented at the Fifty-fifth Annual Meeting of the Southern Thoracic Surgical Association, Austin, TX, Nov 5–8, 2008.

Background: There is no ideal option for pulmonary valve replacement in children. Cryopreserved pulmonary allografts frequently demonstrate early valve regurgitation and may elicit an immune response. To improve these shortcomings, the SynerGraft process (CryoLife, Kennesaw, GA) decellularizes an allograft, leaving only connective tissue, which then becomes repopulated with host cells. A previous study at our institution demonstrated superior short-term durability of the SynerGraft-processed CryoValve SG compared with standard allografts. Longer-term impact of the technology remains unknown.

Methods: A single institution review was performed of all CryoValve SGs implanted between 2001 and 2004. Forty-one CryoValve SG patients and 41 age and diagnosis-matched standard allograft controls were evaluated. Demographics, survival, reintervention, and echocardiographic findings were analyzed.

Results: There were no significant differences between groups in demographics, valve diameter, orthotopic-heterotopic allograft position, or follow-up. For the entire cohort, there was no difference in early or late insufficiency or stenosis at a mean follow-up of 46 ± 14 months. However, freedom from moderate to severe insufficiency (>3+) was significantly better for CryoValve SG patients (p = 0.05). In addition, for patients greater than 2 years of age, CryoValve SGs were significantly less regurgitant (p = 0.045) and stenotic (p = 0.041). Long-term survival was identical at 85% (35 of 41).

Conclusions: When compared with standard allografts, CryoValve SGs demonstrate superior freedom from significant insufficiency at intermediate follow-up. In older children, CryoValve SGs display less insufficiency and stenosis. For infants, patient age, valve diameter, previous conduit, and rapid somatic growth would likely be the predominant factors leading to allograft failure.

This article has been cited by other articles:

				G. Perri, A. Polito, C. Esposito, S. B. Albanese, P. Francalanci, G. Pongiglione, and A. Carotti Early and late failure of tissue-engineered pulmonary valve conduits used for right ventricular outflow tract reconstruction in patients with congenital heart disease Eur J Cardiothorac Surg, January 4, 2012; (2012) ezr221v1. [Abstract] [Full Text] [PDF]

				S. Cebotari, I. Tudorache, A. Ciubotaru, D. Boethig, S. Sarikouch, A. Goerler, A. Lichtenberg, E. Cheptanaru, S. Barnaciuc, A. Cazacu, et al. Use of Fresh Decellularized Allografts for Pulmonary Valve Replacement May Reduce the Reoperation Rate in Children and Young Adults: Early Report Circulation, September 13, 2011; 124(11_suppl_1): S115 - S123. [Abstract] [Full Text] [PDF]

				J. W. Brown, M. Ruzmetov, O. Eltayeb, M. D. Rodefeld, and M. W. Turrentine Performance of SynerGraft Decellularized Pulmonary Homograft in Patients Undergoing a Ross Procedure Ann. Thorac. Surg., February 1, 2011; 91(2): 416 - 423. [Abstract] [Full Text] [PDF]

				R. Zubairi, S. Malik, R. D. B. Jaquiss, M. Imamura, J. Gossett, and W. R. Morrow Risk Factors for Prosthesis Failure in Pulmonary Valve Replacement Ann. Thorac. Surg., February 1, 2011; 91(2): 561 - 565. [Abstract] [Full Text] [PDF]

				P. T. Burch, A. K. Kaza, L. M. Lambert, R. Holubkov, R. E. Shaddy, and J. A. Hawkins Clinical Performance of Decellularized Cryopreserved Valved Allografts Compared With Standard Allografts in the Right Ventricular Outflow Tract Ann. Thorac. Surg., October 1, 2010; 90(4): 1301 - 1306. [Abstract] [Full Text] [PDF]

				A. Ruffer, A. Purbojo, I. Cicha, M. Glockler, S. Potapov, S. Dittrich, and R. A. Cesnjevar Early failure of xenogenous de-cellularised pulmonary valve conduits -- a word of caution! Eur J Cardiothorac Surg, July 1, 2010; 38(1): 78 - 85. [Abstract] [Full Text] [PDF]